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Objective: To test the hypothesis that glycosylation of hemoglobin constitutes a risk factor 
for hypertension.
Methods: A total of 129 relative uniform diabetic subjects (86 women and 42 men) were 
enrolled in a cross-sectional study. Exclusion criteria included alcohol consumption, smoking, 
ischemic heart disease, stroke, neoplasia, renal, hepatic, and chronic inﬂ  ammatory disease. 
Systolic and diastolic pressures were recorded in subsequent days and mean arterial blood 
pressure (MAP) was determined. Hemoglobin glycosylation was measured by determining 
the percentage glycosylated hemoglobin (HbA1c) by means of the automated microparticle 
enzyme immunoassay test.
Results: MAP was found to be independent of the concentration of HbA1c; however, correcting 
MAP for the variability in hematocrit, to evidence the level of vasoconstriction (or vasodilata-
tion) showed that MAP is negatively correlated with the concentration of HbA1c (p for trend 
0.05), when patients treated for hypertension are excluded from the analysis. Patients treated 
for hypertension showed the opposite trend with increasing MAP as HbA1c increased (p for 
the difference in trends 0.05).
Conclusions: Glycosylation per se appears to lead to blood pressure reduction in type 2 diabetic 
patients untreated for hypertension. Treatment for hypertension may be associated with a level 
of endothelial dysfunction that interferes with the antihypertensive effect of HbA1c.
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Introduction
Glycosylated hemoglobin (HbA1c, % HbA1c relative to total hemoglobin, Hb), indicating 
average plasma glucose over 3 months is highly correlated with most of the excess 
mortality risk of diabetes, which rises continuously beyond a 5% glycosylation index 
(~0.7 g/dl concentration) (van Hoeven and Factor 1990; Grossman and Messerli 1996; 
Khaw et al 2001). This relationship is attributed in part to an impairment of the rheological 
properties of blood, leading to increase red blood cell (RBC) stiffness, and alterations of 
plasma viscosity due to the interaction of uncontrolled plasma glucose levels with plasma 
proteins. There is also evidence that glycosylation of hemoglobin impairs nitric oxide 
(NO) related relaxation of human mesenteric vessels (Vallejo et al 2000) and it has been 
shown that Hb glycosylation alters NO binding to Hb thiols, lowering NO bioavailability 
and impairing vasodilatation in rabbit aortic rings (James et al 2004).
Microvascular NO bioavailability is a complex balance of NO production by the 
endothelium and NO scavenging and transport by Hb in RBCs. Blood ﬂ  ow and vis-
cosity determine shear stress on the glycocalix/endothelium modulating the rate of 
production of NO by the endothelium via biochemical mechano transduction (Frangos 
et al 1996). This mechanism provides a form of autoregulation by which increases 
in peripheral vascular resistance due to anatomical or rheological changes increase 
shear stress and the release of endothelial dependant vasodilators, tending to normalize Vascular Health and Risk Management 2008:4(4) 918
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vascular resistance by lowering vessel tone. In normal healthy 
individuals additional autoregulatory mechanisms strive to 
optimize blood pressure and oxygen delivery, compensating 
for changes in blood viscosity due to the natural variability 
of this parameter due to ﬂ  uid intake, alimentation, environ-
mental adaptation, and some disease conditions. This effect 
was demonstrated by Martini and colleagues (2005) who 
increased hematocrit (Hct) and blood viscosity within the 
normal range of variability in healthy experimental animals, 
reducing peripheral vascular resistance and blood pressure 
and increasing cardiac index.
The %HbA1c increase in conditions of poor diabetic con-
trol is associated with increasing blood viscosity (Leiper et al 
1984). Glycosylation of hemoglobin (Hb) may also change 
membrane lipid-protein interactions in RBCs changing their 
internal viscosity, altering viscoelastic properties of erythro-
cyte membranes and impairing RBC deformability (Watala 
et al 1992). RBC deformability in nephrotic patients is 
reduced, an effect associated with the abnormal carbohydrate 
metabolism level and the increased HbA1c characteristic of 
this syndrome (Cecchin et al 1987).
Although glycosylation of Hb is a marker for signiﬁ  cant 
cardiovascular risk, it is not clear whether it constitutes a risk. 
However, cumulative impairment of NO transport by HbA1c 
could constitute a signiﬁ  cant risk factor in view of its direct 
implication in promoting hypertension, ischemia and enhanced 
production of oxygen free radicals. Notably these concepts arise 
primarily from in vitro tests. In the present study we investigated 
the relationship between HbA1c index and concentration, blood 
glucose, mean arterial pressure (MAP), and Hct in a relatively 
uniform diabetic population of Victoria de Durango, a city in 
northern Mexico, to test the hypothesis that glycosylation of 
Hb constitutes a risk factor for hypertension.
Material and methods
A total of 129 subjects (86 women and 42 men) with previ-
ous diagnosis of type 2 diabetes were enrolled in a cross-
sectional study.
Protocol approval was obtained from the Mexican Social 
Security Institute (MSSI) Research Committee and informed 
consent was provided by each individual.
Exclusion criteria included alcohol consumption 30 g 
per week (Reynolds et al 2003), smoking, ischemic heart 
disease, stroke, neoplasia, renal, hepatic, and chronic inﬂ  am-
matory disease.
Blood pressure was measured on subsequent days, accord-
ing with the VI Joint National Committee recommendation 
(JNC 1997). Systolic (SBP) and diastolic (DBP) blood 
pressures were recorded and MAP was determined using 
the relationship:
  MAP = Pdiastolic + 1/3(Psystolic − Pdiastolic) 
Hemoglobin glycosylation was measured by determin-
ing the %HbA1c by means of the automated microparticle 
enzyme immunoassay (IMx, Abbot Laboratories, USA) 
test.
Mean arterial blood pressure was normalized vs. Hct 
using the relationship:
  MAPni MAP i
Hct
Hct
Ave
i
=  
where MAPni is the normalized blood pressure of an 
individual, HctAve is the average Hct in the population sample, 
and Hcti is the Hct of the individual.
The %HbA1c was converted from a relative quantity 
to an absolute concentration in blood by multiplying this 
parameter by Hct, using the average Hct for this population 
of 43.0% and assuming that blood hemoglobin content is 
14.5 g/dl. The following equation was used to normalize 
each individual:
  CHbA ci HbA ci
Hct
Hct
i
Ave
1 1 14 5 =× %.  
where CHbA1ci is the concentration of HbA1c in blood 
in g/dl.
Blood samples (3 ml) were drawn from the antecubital 
vein, 8 to 10 h after fasting, and collected in tubes with 
EDTA for Hct measurements. Hct was measured using a 
microhematocrit centrifuge (13,000 g for 3 min at 20 °C, 
Sol-Bat Centrifuge M-600, Readacrit L-10, Mexico). In 
addition, 3 ml blood samples were drawn in tubes without 
anticoagulants for glucose measurements.
Statistical analysis
Pearson’s analysis was performed to examine the correlation 
between %HbA1c, glucose level, blood pressure, and Hct. For 
the purpose of statistical analysis, all the skewed numerical 
data were transformed by Log n, to obtain a symmetrical 
distribution. Data were analyzed using the statistical package 
SPSS 12.0 (SPSS Inc., Chicago, IL, USA). A 95% conﬁ  dence 
interval (95% CI) was considered, and p  0.05 deﬁ  ned the 
level of statistical signiﬁ  cance.
Results
Previously diagnosed diabetic patients that had undergone 
hypoglycemic treatment for a minimum period of 8 years 
were enrolled from the First Medical Care Level Ofﬁ  ces of Vascular Health and Risk Management 2008:4(4) 919
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the MSSI in Victoria de Durango, Mexico. A total of 187 type 
2 diabetic patients with average glycemia of 213 ± 99 mg/dl 
were screened for hypertension and included in the study if 
SBP was 130 mmHg and/or DBP 85 mmHg. Fifty-eight 
patients (32%) were not included because they did not fulﬁ  ll 
the inclusion-exclusion criteria; ﬁ  nally, a total of 129 diabetic 
patients were enrolled.
Amongst the included persons, 31 (24.0%) were 
hypertensive and received pharmacological treatment with 
captopril (n = 22), nifedipine (n = 4), metoprolol (n = 3), 
and combined therapy (n = 2). None of the patients were 
treated with diuretics, and none of the treatment modalities 
is known to affect the concentration of HbA1c. Patients 
treated for hypertension were analyzed independently from 
the non treated diabetic patients; however the untreated 
population was not statistically different from the treated 
population with the exception of blood pressure (p  0.001) 
as shown in Table 1.
The correlation between MAP and HbA1c % for the 
whole population sample of 129 patients including patients 
treated and untreated for hypertension was negative but not 
statistically signiﬁ  cant (p = 0.24).
The correlation between MAP and HbA1c when patients 
were separated into treated vs. non treated for hyperten-
sion was negative for untreated patients and positive for 
treated patients, however neither correlation was signiﬁ  cant, 
although the difference in trends approached signiﬁ  cance 
(p = 0.06).
Normalizing MAP relative to Hct, yielded a negative 
nonsignificant (p = 0.19) correlation between MAP of 
patients not treated for hypertension and %HbA1c. Patients 
treated for hypertension showed a signiﬁ  cant positive trend 
(p = 0.02), and the difference in trends was highly signiﬁ  cant 
(p = 0.007), a result shown in Figure 1.
The correlation between normalized MAP and HbA1c 
converted from % of blood hemoglobin to actual concentration 
(g/dl) is shown in Figure 2 for diabetics untreated and treated 
for hypertension. The trend had a statistically signiﬁ  cant 
(p = 0.04) negative correlation for untreated patients and 
a positive nonsigniﬁ  cant (p = 0.22) correlation for treated 
patients. The difference in trends however was statistically 
signiﬁ  cant (p = 0.04).
The decrease of blood pressure as a function of increased 
%HbA1c suggests that a factor affecting the relationship 
between MAP and Hct may be microalbuminuria, which is 
related to increased permeability caused by HbA1c, and which 
could affect Hct. However, although there was a slightly posi-
tive functional dependence between these parameters, it was 
not statistically signiﬁ  cant (r2 = 0.002 and p = 0.66).
Discussion
The principal ﬁ  nding of this study is that MAP in a compara-
tively uniform population of diabetic of fairly similar racial 
Table 1 Population characteristics of diabetic type 2 patients treated 
for hypertension vs untreated
 Untreated  Treated
Number of patients  98  31
Female/male 67/31  20/11
Age, years  52.6 ± 1.4  51.5 ± 4.2
Glucose 220  ± 78  192 ± 94
Cholesterol 252  ± 58  240 ± 52
Hematocrit, %  42.8 ± 2.4  43.7 ± 4.5
HbA1c, %  9.3 ± 2.6  9.2 ± 2.3
Mean arterial blood   89.7 ± 13.6  101.8 ±12.5
pressure, mmHg
Notes: Mean ± standard deviation.  All parameters not statistically different (p  0.05), 
with the exception of mean arterial blood pressure (p  0.001).
Abbreviation: HbA1c, glycosylated hemoglobin.
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Figure 1 Mean arterial blood pressure (MAP, mmHg) normalized relative to hematocrit 
for each patient versus glycosylation index. This normalization approximately excludes 
the effects of blood viscosity on MAP variability due to the distribution of Hct in 
the population. Patients untreated for hypertension had a negative MAP versus Hb 
glycosylation trend with slope: −0.71 ± 0.53 mmHg/% HbA1c (p  0.19). The trend for 
patients treated for hypertension was positive, 2.14 ± 0.88 (p  0.88). Therefore MAP 
is basically independent of %HbA1c. Although neither trend was statically signiﬁ  cant, 
the difference between trends was highly signiﬁ  cant with p = 0.007.
Abbreviations: Hb, hemoglobin; HbA1c, glycosylated hemoglobin; Hct, hematocrit.Vascular Health and Risk Management 2008:4(4) 920
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and ambient characteristic is unrelated to the glycosylation 
index of Hb when this ranges from 0.5 to 2.6 g/dl plasma. 
Separating from this population individuals treated for hyper-
tension shows that there is a statistically signiﬁ  cant negative 
correlation between MAP normalized relative to Hct versus 
the concentration of HbA1c.
Normalizing MAP relative to Hct renders the measured 
blood pressure independent of blood viscosity, and reveals 
whether MAP is a function of vascular regulation or the 
change in ﬂ  ow properties of blood. Thus normalizing MAP 
relative to Hct is a means for identifying effects on blood 
pressure due to vasoactivity vs. those due to the viscosity 
of blood determined by Hct, which presents a natural vari-
ability in the population. When the effect of blood viscosity 
is approximately neutralized by the normalization procedure 
blood pressure becomes directly related to the level of tone 
of the vasculature, ie, whether it is constricted or vasodilated, 
if we assume that anomalies of cardiac function, circulating 
blood volume, baroreceptor reﬂ  exes, etc., randomly affect 
blood pressure and are unrelated to Hb glycosylation. In 
the present case, it appears that individuals not treated for 
hypertension may be progressively vasodilated in proportion 
of the increase of total and/or relative HbAc1 concentration 
increases. In this study we normalized blood pressure versus 
Hct since a previous study by Salazar-Vázquez and colleagues 
(2006), in the same population of diabetic patients, shows a 
“U” shaped distribution of MAP versus Hct. Regarding the 
statistical differences found between the different treatments 
of the data, it appears that the assessment of cardiovascular 
risk may be more evident when using hematocrit corrected 
MAP data versus %HBA1c. However the fundamental dif-
ference between the two populations is expressed regardless 
of the difference in treatment of the data.
Since 8%–10% HbA1c is considered to be a threshold 
beyond which the effects of hemoglobin glycosylation 
become signiﬁ  cant we determined MAP for patients not 
treated for hypertension below and above 9% HbA1c, and 
found that below the threshold MAP was 86.2 ± 3.9 mmHg 
and 93.1 ± 12.5 mmHg above the threshold, the difference 
being statistically signiﬁ  cant (p  0.001), conﬁ  rming the 
trend found when the data was analyzed as a whole. These 
results show that Hb glycosylation is not associated with 
the increase of the anatomical component of peripheral 
vascular resistance in individuals not treated for hyperten-
sion. Therefore the impairment of NO bioavalability leading 
to vasoconstriction postulated by in vitro studies in aortic 
rings does not appear to obtain in vivo (James et al 2004). It 
is furthermore apparent that solely on the basis of the effect 
that vasodilation and vasoconstriction has on blood pres-
sure, there is no evidence that “…glycosylation impairs the 
NO vasodilator function of RBCs within the physiological 
range of tissue oxygenation” (James et al 2004). Remarkably 
James and colleagues (2004) found signiﬁ  cant inhibition 
of hypoxic relaxation effects when HbA1c was 10.7% of 
human red blood cell was used in the perfusion of rabbit 
aortic rings. Conversely, our study failed to demonstrate an 
effect on blood pressure when individuals had HbA1c that 
was as much as 26% of the total RBCs. Thus the rabbit aor-
tic rings study exposed to human glycosylated RBCs show 
vasoactivity that may be uncorrelated to that expected in a 
human cross-sectional study.
Translation and relevance of isolated tissue studies to in 
vivo conditions in humans is always a difﬁ  cult endeavor, 
because the isolated tissue is not exposed to the full spectrum 
of phenomena operational in vivo. While it is undeniable 
that aortic rings exhibit a greater constriction tendency when 
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Figure 2 Normalized mean arterial blood pressure (MAP, mmHg) as a function of 
concentration of HbA1c (%HbA1c times the calculated hemoglobin concentration 
in each patient). This normalization relates MAP directly to the concentration of 
glycosylated Hb in blood. Patients not treated for hypertension had a negative MAP 
vs. HbAc1 concentration (slope − 7.36 ± 3.57 mmHg/HbAc1 g/ml) that was signiﬁ  cant 
(p = 0.04), a result opposite from that predicted by experimental studies in aortic rings. 
The trend for patient treated for hypertension was 8.31 ± 0.67 (p = 0.22) which was 
not signiﬁ  cant. The difference between slopes was signiﬁ  cant with p = 0.04.
Abbreviations: Hb, hemoglobin; HbA1c, glycosylated hemoglobin.Vascular Health and Risk Management 2008:4(4) 921
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exposed to glycosylated RBCs, our study shows that this 
phenomenon does not correspond to the increase of blood 
vessel tone dependant peripheral vascular resistance in the 
population at risk, and that the opposite may obtain.
There are several mechanisms that may in part explain 
our ﬁ  ndings. A mechanism by which glycosylation of Hb is 
proposed to be vasoactive is via the formation of reactive 
oxygen species (ROS) (Angulo et al 1996) however this pro-
cess is signiﬁ  cantly mitigated inside RBCs. Glycosylation of 
Hb also lowers oxygen carrying capacity, promoting hypoxia 
and its related systemic vascular vasodilatory adaptations and 
responses (Paffett and Walker 2007).
Glycosylation of Hb as well as increased glucose levels 
tends to affect primarily RBC properties, lowering the RBC 
ﬂ  exibility and increasing aggregability, the latter potentially 
increasing blood viscosity (Buhler et al 2001). Blood viscos-
ity is one of the determinants of shear stress and peripheral 
vascular resistance via mechano-transduction. It should be 
noted that increased blood viscosity is not necessarily patho-
logical, since it can be instrumental in increasing shear stress, 
enhancing the production of endothelial NO, compensating 
for the effect of viscosity on peripheral vascular resistance 
via vasodilatation. In this context decreased RBC ﬂ  exibility 
has a moderate effect in increasing blood viscosity, which 
may in part explain the tendency for a negative correlation 
between glycosylation index and blood pressure.
The characteristic of the population studied were rela-
tively uniform, in terms of age, duration of diabetes, cho-
lesterol, and hematocrit, but differed signiﬁ  cantly in MAP 
which was the cause for treatment of this segment of the 
population. The ﬁ  nding that the subgroup of patients treated 
for hypertension presents a statistically signiﬁ  cant positive 
correlation with the increase of HbA1c suggests that in this 
population that requires a direct intervention for the control 
of MAP, endothelial dysfunction was signiﬁ  cant. Conse-
quently the presence of glycosylated Hb did not provide any 
compensatory effects at the level of the endothelium. In this 
context it appears that in diabetic patients that require treat-
ment for hypertension hemoglobin glycosylation aggravates 
the consequences of endothelial dysfunction.
In conclusion, the existence of a negative, statistically 
signiﬁ  cant correlation between MAP and the concentration 
of glycosylated Hb suggests that this parameter is not an 
indicator of hypertension. Increased HbA1c concentration 
should increase blood viscosity, peripheral vascular resistance, 
and blood pressure. Furthermore glycosylation of hemoglobin 
per se should impair the NO vasodilator function of RBC. 
However the lack or opposite consequence of these effects 
was found in a population of type 2 diabetic patients not treated 
for hypertension. The effects of hemoglobin glycosylation 
are mostly deduced from in vitro and tissue studies that do 
not correspond to physiological conditions, highlighting the 
difﬁ  culty of translating experimental ﬁ  ndings to conditions in 
the human population. In vivo increased blood viscosity also 
leads to increased shear stress and therefore NO production 
by the endothelium, therefore if endothelial impairment is 
not present, then the potential, albeit small, increase in blood 
viscosity due to Hb glycosylation may be beneﬁ  cial, although 
other rheological effects such as decreased RBC ﬂ  exibility 
may adversely affect capillary perfusion. Finally diabetic 
patients requiring treatment for hypertension appear unable 
to compensate for the increased levels of HbA1c, conﬁ  rming 
the presence of endothelial dysfunction, and possibly the 
impairment of hypoxic dilatation regulation.
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